<DOC>
	<DOCNO>NCT02822989</DOCNO>
	<brief_summary>Systemic Lupus Erythematosus ( SLE ) chronic autoimmune , inflammatory disease musculoskeletal pain one common symptom . This study investigate whether transcutaneous stimulation vagus nerve decrease lupus musculoskeletal pain . This study additionally investigate biologic effect vagus nerve stimulation inflammation . It first clinical study use one body 's pathway modulate immune system inflammatory response , cholinergic anti-inflammatory pathway , SLE .</brief_summary>
	<brief_title>Using Cholinergic Anit-Inflammatory Pathway Treat Systemic Lupus Musculoskeletal Pain</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Musculoskeletal Pain</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<criteria>1 . Age ≥18 year , 2 . SLE ( define ACR SLICC criterion ) , 3 . Musculoskeletal pain ≥ 4 nonanchored VAS 10 cm scale 4 . BILAG C Musculoskeletal Domain BILAG 2004 5 . If corticosteroid , dose must stable ≤ 10mg/day ( prednisone equivalent ) least 28 day baseline , 6 . If background immunosuppressive treatment dose must stable least 28 day baseline 7 . Able willing give write informed consent comply requirement study protocol . 1 . Treatment rituximab within one year baseline ( subject previous treatment rituximab enter study documentation B cell repletion ) , 2 . Treatment cyclophosphamide within 2 month baseline , 3 . Expectation increase steroid and/or immunosuppressive treatment , 4 . Antiphospholipid syndrome , 5 . Fibromyalgia ( fibromyalgia define score &gt; 13 Fibromyalgia Symptom Scale ( FSS ) . 6 . Treatment anticholinergic medication , include counter medication , 7 . Implantable electronic device pacemaker , defibrillator , hear aid , cochlear implant deep brain stimulators . 8 . Current tobacco nicotine user , 9 . Joint replacement within 60 day prior study enrollment plan within course study , 10 . Any planned surgical procedure require general anesthesia within course study , 11 . Intraarticular cortisone injection within 28 day start study , 12 . Chronic inflammatory disorder apart SLE affect joint , 13 . Investigational drug and/or treatment 28 day seven halflives investigational drug prior start study drug dosing ( Day 0 ) , whichever great length time , 14 . Active infection include hepatitis B hepatitis C baseline , 15 . Any condition , opinion investigator , would jeopardize subject 's safety follow exposure study intervention , 16 . Pregnancy lactation , 17 . Comorbid disease may require administration corticosteroid use , 18 . Inability comply study followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Musculoskeletal Pain</keyword>
	<keyword>Inflammation</keyword>
</DOC>